
Aurinia Pharmaceuticals fell 8.8% from $16.11 to $14.70, behind the S&P 500's +3.2%. Its worst day was Dec 3 (−7.5%), and its low came Mar 13 at $13.95.
Nov 24, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Aurinia Pharmaceuticals shares fell 7.5%, while the S&P 500 rose 0.1%.
−7.5%, the year's worst day · S&P 500 +0.1%
EPS of $0.26 beat the $0.21 estimate on $77.1M revenue (est. $74.6M); FY revenue guidance of $315.0M–$325.0M against the $320.7M consensus.
Story events cover the past 12 months · Times ET
−3.2% · S&P 500 −0.6%
Aurinia Pharmaceuticals closed at its lowest level of the year, 13.4% below where the year started.
−2.9% · S&P 500 −0.6%
Aurinia Pharmaceuticals shares rose 6.0%, while the S&P 500 rose 2.9%.
+6.0% · S&P 500 +2.9%
EPS of $0.25 beat the $0.19 estimate on $77.7M revenue (est. $77.1M); FY revenue guidance of $315.0M–$325.0M against the $327.0M consensus.
−6.8% · S&P 500 −0.3%
Aurinia Pharmaceuticals closed at its highest level of the year, 15.6% above where the year started.
+4.1% · S&P 500 0.0%
EPS of $0.28 beat the $0.24 estimate on $83.2M revenue (est. $80.8M); FY revenue guidance of $315.0M–$325.0M against the $326.0M consensus.
+6.2% · S&P 500 −0.2%
Aurinia Pharmaceuticals shares rose 6.8%, while the S&P 500 fell 0.8%.
+6.8%, the year's best day · S&P 500 −0.8%
EPS of $0.23 beat the $0.22 estimate on $83.7M revenue (est. $84.3M); FY revenue guidance of $325.0M–$330.0M against the $331.5M consensus.
−3.3% · S&P 500 −1.8%
Where it ended: a close of $14.70 on Nov 20, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $0.22, revenue est. $85.5M).
Nothing in the past 12 months.
All AUPH dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AUPH and SPY from Benzinga historical bars. Not investment advice.